Increased expression of HMMR in renal cell carcinoma is an independent prognostic factor

Zhang,Henglan; Li,Ling; Wang,Dongqing

doi:10.3892/ol.2022.13614

Increased expression of HMMR in renal cell carcinoma is an independent prognostic factor

Authors:
- Henglan Zhang
- Ling Li
- Dongqing Wang
View Affiliations

Affiliations: Department of Oncology, Jinan Third People's Hospital, Jinan, Shandong 250132, P.R. China, Department of Oncology, Xintai People's Hospital, Xintai, Shandong 271200, P.R. China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China
Published online on: November 24, 2022 https://doi.org/10.3892/ol.2022.13614
Article Number: 28
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated how abnormal expression of hyaluronan‑mediated mobility receptor (HMMR) in renal cell carcinoma (RCC) tissue affects the growth of RCC cells and the association between expression of HMMR and pathological staging and prognosis of patients with RCC. Reverse transcription‑quantitative PCR was used to measure the expression of HMMR mRNA in RCC tissue and cell lines. For the prediction of HMMR gene expression, The Cancer Genome Atlas online database was utilized to compare differential gene expression of HMMR in normal renal and RCC tissue. Cell Counting Kit‑8 assay was used to examine cell proliferation. The expression of HMMR increased in RCC tissue and renal cancer cell lines. The expression of HMMR was an independent prognostic factor for 5‑year and disease‑free survival in patients with RCC. The silencing of HMMR expression decreased the expression of Cyclin B1 and inhibited the proliferation of RCC cells. Overexpression of HMMR promoted the expression of Cyclin B1 and cell proliferation. The present study demonstrated that the expression of HMMR was significantly upregulated in RCC and was an independent prognostic factor for RCC. HMMR may be involved in the occurrence of RCC by regulating Cyclin B1.

View Figures

View References

1	Terrone C, Guercio S, De Luca S, Poggio M, Castelli E, Scoffone CM, Tarabuzzi R, Scarpa RM, Fontana D and Rossetti SR: Number of nodes examined and staging accuracy in renal cell carcinoma (RCC). BJU Int. 91:37–40. 2003. View Article : Google Scholar
2	Motzer RJ, Russo P, Nanus DM and Berg WJ: Renal-cell carcinoma. Curr Probl Cancer. 21:185–232. 1997. View Article : Google Scholar : PubMed/NCBI
3	Oosterwijk E, Stillebroer AB and Mulders PFA: Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic, and Therapeutic Target in Renal Cell Carcinoma. Renal Cell Carcinoma. Figlin R, Rathmell W and Rini B: Springer; Boston, MA: 2012, View Article : Google Scholar
4	Rini BI, Rathmell WK and Godley P: Renal cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar
5	Trump DL: 1. Sorafenib in advanced clear-cell renal-cell carcinoma. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM; TARGET Study Group, : Department of Medicine, Institut Gustave Roussy; Villejuif, France: Urol Oncol Semin Orig Investig. 25. pp. 443–445. 2007
6	Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
8	Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I, Philippé J, Berneman ZN, Plum J, Taghon T, et al: RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica. 97:1539–1547. 2012. View Article : Google Scholar
9	Sohr S and Engeland K: RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle. 7:3448–3460. 2008. View Article : Google Scholar : PubMed/NCBI
10	Tilghman J, Wu H, Sang Y, Shi X, Guerrero-Cazares H, Quinones-Hinojosa A, Eberhart CG, Laterra J and Ying M: HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells. Cancer Res. 74:3168–3179. 2014. View Article : Google Scholar : PubMed/NCBI
11	Esguerra KV, Tolg C, Akentieva N, Price M, Cho CF, Lewis JD, McCarthy JB, Turley EA and Luyt LG: Identification, design and synthesis of tubulin-derived peptides as novel hyaluronan mimetic ligands for the receptor for hyaluronan-mediated motility (RHAMM/HMMR). Integr Biol (Camb). 7:1547–1560. 2015. View Article : Google Scholar : PubMed/NCBI
12	Yang C, Li C, Zhang P, Wu W and Jiang X: Redox responsive hyaluronic acid nanogels for treating RHAMM (CD168) over-expressive cancer, both primary and metastatic tumors. Theranostics. 7:1719–1734. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ahmad S, Kolli S, Li DQ, de Paiva CS, Pryzborski S, Dimmick I, Armstrong L, Figueiredo FC and Lako M: A putative role for RHAMM/HMMR as a negative marker of stem cell-containing population of human limbal epithelial cells. Stem Cells. 26:1609–1619. 2008. View Article : Google Scholar : PubMed/NCBI
14	Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J and Turley EA: The hyaluronan receptors CD44 AND Rhamm (CD168) form complexes with ERK1,2, that sustain high basal motility in breast cancer cells. J Biol Chem. 282:16667–16680. 2007. View Article : Google Scholar : PubMed/NCBI
15	Jöhrens K, Anagnostopoulos I, Dommerich S, Raguse JD, Szczepek AJ, Klauschen F and Stölzel K: Expression patterns of CD168 correlate with the stage and grade of squamous cell carcinoma of head and neck. Mol Clin Oncol. 6:597–602. 2017. View Article : Google Scholar
16	Lin SL, Chang D, Chiang A and Ying SY: Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogenesis. 29:282–290. 2008. View Article : Google Scholar : PubMed/NCBI
17	Chen H, Connell M, Mei L, Gsd R and Maxwell CA: The nonmotor adaptor HMMR dampens Eg5-mediated forces to preserve the kinetics and integrity of chromosome segregation. Mol Biol Cell. 29:786–796. 2018. View Article : Google Scholar
18	Greiner J, Ringhoffer M, Li L, Barth T, Wölfel T, Döhner H and Schmitt M: The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a leukemia associated antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML). Cancer Cell Int. 4 (Suppl 1):S552004. View Article : Google Scholar
19	Ishigami S, Ueno S, Nishizono Y, Matsumoto M, Kurahara H, Arigami T, Uchikado Y, Setoyama T, Arima H, Yoshiaki K, et al: Prognostic impact of CD168 expression in gastric cancer. BMC Cancer. 11:1062011. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Missinato MA, Tobita K, Romano N, Carroll JA and Tsang M: Extracellular component hyaluronic acid and its receptor Hmmr are required for epicardial EMT during heart regeneration. Cardiovasc Res. 107:487–498. 2015. View Article : Google Scholar : PubMed/NCBI
22	Heikinheimo K, Kurppa KJ, Laiho A, Peltonen S, Berdal A, Bouattour A, Ruhin B, Catón J, Thesleff I, Leivo I and Morgan PR: Early dental epithelial transcription factors distinguish ameloblastoma from keratocystic odontogenic tumor. J Dent Res. 94:101–111. 2015. View Article : Google Scholar : PubMed/NCBI
23	Bidadi B, Liu D, Kalari KR, Rubner M, Hein A, Beckmann MW, Rack B, Janni W, Fasching PA, Weinshilboum RM and Wang L: Pathway-based analysis of genome-wide association data identified SNPs in HMMR as biomarker for chemotherapy-induced neutropenia in breast cancer patients. Front Pharmacol. 9:1582018. View Article : Google Scholar
24	Stevens LE, Zhao M, Liu Z and Nguyen D: Abstract 2269: A novel molecular subset of metastatic lung adenocarcinoma is defined by the function of the proteoglycan receptor HMMR. Cancer Res. 75 (Suppl 15):S22692015. View Article : Google Scholar
25	Tang XH, Osei-Sarfo K, Urvalek AM, Zhang T, Scognamiglio T and Gudas LJ: Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci USA. 111:8907–8912. 2014. View Article : Google Scholar : PubMed/NCBI
26	Pinaire N, Johnson P, Chari N, Spurgers K, Meyn R and McDonnell T: Abstract #5312: Novel transcriptional targets of p53 may inhibit cell migration. Cancer Res. 69 (Suppl):S53122009. View Article : Google Scholar
27	Keane M, Craig T, Alföldi J, Berlin AM, Johnson J, Seluanov A, Gorbunova V, Di Palma F, Lindblad-Toh K, Church GM and de Magalhães JP: The naked mole rat genome resource: Facilitating analyses of cancer and longevity-related adaptations. Bioinformatics. 30:3558–3560. 2014. View Article : Google Scholar : PubMed/NCBI
28	Chu TLH, Connell M, Zhou LX, He ZC, Won J, Chen H, Rahavi SMR, Mohan P, Nemirovsky O, Fotovati A, et al: Cell Cycle-Dependent Tumor Engraftment and Migration Are Enabled by Aurora-A. Mol Cancer Res. 16:16–31. 2018. View Article : Google Scholar : PubMed/NCBI
29	Murphy JM, Park H and Lim STS: FAK and Pyk2 in disease. Front Biol. 11:1–9. 2016. View Article : Google Scholar